The role of Asprosin in the diagnosis of diabetic and non-diabetic patients with sepsis

Abstract

Sepsis is among the major causes of mortality in the world due to its delayed diagnosis and inadequate treatment. Due to the high morbidity and mortality rates, a widely accepted biomarker is required for its diagnosis. Present study aimed to evaluate the serum asprosin levels in septic patients and determine its potential use as a biomarker for its diagnosis. A prospective cohort study was performed with total 81 participants. These were divided in two groups, i.e., 54 septic patients and 27 healthy volunteers (control group). Among 54 septic participants, half (27) were diabetic, and half (27) were nondiabetic. Blood samples (3 mL) were collected from the control group and the patients who were diagnosed with sepsis and transferred to serum seperator tube. Samples were fractioned and stored at −80 ◦C for further evaluation. These samples were used for the measurement of serum asprosin levels. Demographic characteristics and laboratory data of the patients were recorded in the study form prepared previously. The serum asprosin levels in the control group were 4.1 ± 1.4 ng/mL, 32.8 ± 7 ng/mL in the non-diabetic septic patients and 90.7 ± 5.5 ng/mL in diabetic septic patients. The asprosin level in the non-diabetic group were higher as compared to the control group (p: 0.012), and it was statistically significantly higher in the diabetic group compared to the non-diabetic septic and control groups (both: p < 0.001). Serum asprosin levels were significantly higher in patients with sepsis specially having diabetes. Serum asprosin levels may be beneficial for the diagnosis of sepsis especially in diabetic patients along with the other laboratory parameters white blood cells (WBC), C-reactive protein (CRP), sequential organ failure assessment score (SOFA score) and fewer.